Relata^®

Ruxolitinib

Product Information

Proprietary Name: Relata®
Generic Name: Ruxolitinib
Dosage Form: Tablet
Strengths: 5 mg, 10 mg, 15 mg, 20 mg
Indications: Myelofibrosis, Polycythemia Vera, Graft-versus-Host Disease (GvHD)

Download Leaflet

Oncology

Relata®

Ruxolitinib is indicated for the treatment of myelofibrosis, polycythemia vera, graft-versus-host disease (GvHD).

Apply for a Job Position

Curious about job opportunities?

Signup for a job

Products

Support

Company

Follow Us

© NanoAlvand. All rights reserved. Powered by ِDGN.